```json
{
"content": [
{
"type": "paragraph",
"content": "The Drugs for Brucellosis market encompasses treatments for a bacterial zoonotic disease affecting humans and animals, primarily caused by Brucella species. With rising zoonotic disease awareness and livestock health concerns, this market holds strategic relevance in global public and veterinary health. The global market size was projected at $280 million in 2025, reflecting steady growth driven by increasing livestock production and regulatory initiatives to mitigate disease outbreaks. The market forecast for 2026–2033 anticipates a compound annual growth rate (CAGR) of 4.5%, with industry expansion fueled by advancements in antimicrobial therapies and regional government funding for animal health programs."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Antibiotics", "Vaccines", "Others"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270], // Antibiotics
[50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110], // Vaccines
[30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54] // Others
]
}
},
{
"type": "paragraph",
"content": "Key forces shaping the industry include the development of multi-drug regimens to combat antibiotic resistance and increased investment in veterinary vaccines. North America remains the largest market due to advanced healthcare infrastructure and stringent livestock health regulations, while Asia-Pacific is the fastest-growing region, driven by expanding dairy and meat production. Supply-chain resilience and partnerships between pharmaceutical firms and agricultural bodies are critical to addressing regional disparities in treatment access. Strategic innovations, such as targeted therapies and rapid diagnostics, are expected to redefine the Drugs for Brucellosis market size and competitive landscape through 2033."
}
]
}
```
